Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665345 | 0.87 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL17522151 | 0.84 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16665362 | 0.84 | FGFR4 (0.43) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16656028 | 0.81 | FGFR1 (0.63) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16665360 | 0.76 | FGFR1 (0.60) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071783 | 0.76 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL15434047 | 0.74 | FGFR1 (0.68) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL23653402 | 0.72 | FGFR4 (0.48) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071525 | 0.71 | FGFR4 (0.75) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16665308 | 0.70 | FGFR1 (0.62) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |